Glonghui, March 5 | Citigroup published a report stating that the revenue forecast for Zhongsheng Pharmaceuticals remained unchanged, but due to the offset of minority shareholders' equity percentage, it lowered its earnings forecast per share. The target price was lowered from HK$9 to HK$7.4, maintaining the “buy” rating.
大行评级｜花旗：下调中生制药目标价至7.4港元 维持“买入”评级
Bank Rating | Citibank: Lowering the target price of Zhongsheng Pharmaceuticals to HK$7.4 to maintain a “buy” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.